Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging

Magnetic Resonance in Medicine

Volumn 46, Issue 1, 2001, Pages 49-57

  Mueller Lisse, Ullrich G ^a   Swanson, Mark G ^a   Vigneron, Daniel B ^a   Hricak, Hedvig ^a   Bessette, André ^a   Males, Ryan G ^a   Wood, Penelope J ^a   Noworolski, Susan ^a   Nelson, Sarah J ^a   Barken, Israel ^b   Carroll, Peter R ^c   Kurhanewicz, John ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Prostate Cancer Research and Education Foundation   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Choline; Citrate; Hormone deprivation therapy; MRI; MRSI; Prostate cancer; PSA

Indexed keywords

AMINES; BIOMOLECULES; DISEASES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; METABOLISM; METABOLITES; UROLOGY;

CHOLINE; CITRATE; DEPRIVATION THERAPY; MRSI; PROSTATE CANCERS;

PATIENT TREATMENT;

ANTIANDROGEN; CHOLINE; CITRIC ACID; CREATININE; GONADORELIN AGONIST; POLYAMINE;

ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE DEPRIVATION THERAPY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; METABOLISM; METABOLITE; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; THREE DIMENSIONAL IMAGING;

EID: 0034957473     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.1159     Document Type: Article

References (40)

1. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer
2. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: Results of a phase II study
3. Effects of neoadjuvant androgen deprivation therapy on prostatic cancer
4. 2 prostate cancer: Interim results of a prospective randomized trial
5. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NO MO prostatic carcinoma
6. Pathological changes in prostate lesions after androgen manipulation
7. Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary
8. Mechanistic concepts in androgen-dependence of prostate cancer
9. The biology of hormone refractory prostate cancer. Why does it develop?
10. The prostate: MR imaging and spectroscopy. Present and future
11. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer
12. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution
13. Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging - Clinicopathologic study
14. Prostate cancer: Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging
15. Prostate cancer: Metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging
16. Detection of locally recurrent prostate cancer after cryosurgery: Evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy
17. Detection of recurrent prostate cancer after cryosurgery
18. Testosterone regulates pyruvate dehydrogenase activity of prostate mitochondria
19. Testosterone stimulates the biosynthesis of m-aconitase and citrate oxidation in prostate epithelial cells
20. Testosterone and prolactin stimulation of mitochondrial aconitase in pig prostate epithelial cells
21. Apoptosis in prostatic adenocarcinoma following complete androgen ablation
22. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
23. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy
24. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils
25. Spatial localization in NMR spectroscopy in vivo
26. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING)
27. Surface coil MR imaging of the human brain with an analytic reception profile correction
28. Localizing prostate cancer in the presence of postbiopsy changes on MR images: Role of proton MR spectroscopic imaging
29. Hormonal ablation of prostatic cancer: Effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging
30. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma
31. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis
32. Secondary endocrine treatment of prostate cancer
33. Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate
34. Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia
35. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging
36. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer
37. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
38. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy
39. Histologic effects of radiation therapy and total androgen blockade on prostate cancer